Skip to main content

Table 3 Adjusted hazard ratios for 5-year OS in patients with IBC presenting with stage IV disease

From: Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer

 

Hazard ratio

(95% CI)

p value

Age

1.01

1.00–1.01

0.168

Year of diagnosis

0.98

0.95–1.02

0.352

Clinical nodal stage

 N0

1 (ref)

  

 N1

1.15

0.78–1.68

0.468

 N2

1.23

0.74–2.07

0.414

 N3

1.32

0.88–1.99

0.174

Surgery

 No

1 (ref)

  

 Yes

0.56

0.42–0.74

< 0.001

Chemotherapy

 Yes

1 (ref)

  

 No

1.62

1.24–2.14

< 0.001

Targeted therapy

 Yes

1 (ref)

  

 No

2.76

1.70–3.05

< 0.001

Antihormonal therapy

 Yes

1 (ref)

  

 No

2.16

1.62–2.89

< 0.001

Radiation therapy

 Yes

1 (ref)

  

 No

1.11

0.84–1.46

0.457

Molecular subtype

 HR+/HER2−

1 (Ref)

  

 HR+/HER2+

1.17

0.86–1.61

0.319

 HR−/HER2+

1.59

1.12–2.24

0.009

 HR−/HER2−

1.94

1.41–2.67

< 0.001

Location of metastases

 Bone only

1 (ref)

  

 Liver only

0.86

0.56–1.33

0.507

 Lung only

1.27

0.81–1.99

0.292

 Other

0.99

0.69–1.40

0.934

 Multiple organs

1.32

1.04–1.68

0.021

  1. Abbreviations: ref. refererence, OR odds ratio, CI confidence interval, HR hormone receptor, HER2 human epidermal growth factor receptor-2. p values indicated in italics are considered as statistically significant (p < 0.05)